學門類別
最新個案
- Leadership Imperatives in an AI World
- Vodafone Idea Merger - Unpacking IS Integration Strategies
- V21 Landmarks Pvt. Ltd: Scaling Newer Heights in Real Estate Entrepreneurship
- Snapchat’s Dilemma: Growth or Financial Sustainability
- Did I Just Cross the Line and Harass a Colleague?
- Predicting the Future Impacts of AI: McLuhan’s Tetrad Framework
- Porsche Drive (A) and (B): Student Spreadsheet
- Porsche Drive (B): Vehicle Subscription Strategy
- TNT Assignment: Financial Ratio Code Cracker
- Winsol: An Opportunity For Solar Expansion
Glenmark Generics Inc.: Launch @ Risk
內容大綱
The U.S.-based executive vice-president (EVP) of Glenmark Generics Inc., the subsidiary of an Indian generic manufacturer, is weighing his options on whether or not to proceed with what is known as a Launch @ Risk in the U.S. market. Defined as a “risk taken by a generic company when it puts a product on the market before resolving outstanding patent lawsuits against it,” Launch @ Risk is a widely acknowledged route to gain an entry into the world's largest and most profitable pharmaceutical market. The focal product is the generic version of a hypertension drug whose patent is set to expire in 2015. Glenmark Generics has just secured approval from the U.S. Food and Drugs Administration (FDA) to launch a low-cost generic version of the patented drug but the FDA approval is being contested in a court of law by the patent holder. While awaiting the court’s ruling, the EVP must evaluate his company's options and decide whether to proceed, in the interim, with the product launch.
學習目標
<ul><li>To present a business opportunity where taking on some risk holds the promise of significant returns.</li><li>To resolve a situation requiring a balance between risk and return.</li><li>To structure a complex decision situation involving significant uncertainties.</li><ul>